Dupilumab reduces OCS use and improves lung function in patients with severe OCS-dependent asthma
M. Gurnell (Cambridge, United Kingdom), C. Domingo (Barcelona, Spain), K. Rabe (Grosshansdorf, Germany), A. Menzies-Gow (London, United Kingdom), D. Price (Midview City, Singapore), G. Brusselle (Ghent, Belgium), M. Wechsler (Denver, CO, United States), C. Xia (Tarrytown, NY, United States), N. Pandit-Abid (Bridgewater, NJ, United States), R. Gall (Tarrytown, NY, United States), J. Jacob-Nara (Bridgewater, NJ, United States), P. Rowe (Bridgewater, NJ, United States), Y. Deniz (Tarrytown, NY, United States), S. Siddiqui (Tarrytown, NY, United States)
Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Gurnell (Cambridge, United Kingdom), C. Domingo (Barcelona, Spain), K. Rabe (Grosshansdorf, Germany), A. Menzies-Gow (London, United Kingdom), D. Price (Midview City, Singapore), G. Brusselle (Ghent, Belgium), M. Wechsler (Denver, CO, United States), C. Xia (Tarrytown, NY, United States), N. Pandit-Abid (Bridgewater, NJ, United States), R. Gall (Tarrytown, NY, United States), J. Jacob-Nara (Bridgewater, NJ, United States), P. Rowe (Bridgewater, NJ, United States), Y. Deniz (Tarrytown, NY, United States), S. Siddiqui (Tarrytown, NY, United States). Dupilumab reduces OCS use and improves lung function in patients with severe OCS-dependent asthma. 3212
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|